[PCSK9 - break through in the prevention and treatment of arteriosclerosis?].
Lewartowski
Bohdan
B
Zakład Fizjologii Klinicznej, Centrum Medyczne Kształcenia Podyplomowego, Warszawa. blew@cmkp.edu.pl
D000818:Animals; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000235:genetics*; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D011973:Receptors, LDL / Q000187:drug effects; D012697:Serine Endopeptidases / Q000187:drug effects* / Q000235:genetics*
D000960:Hypolipidemic Agents; D011973:Receptors, LDL; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases